Skip to main content

Table 3 Factors associated with greater assessed ASDAS-CRP after 3 months (12 weeks) of anti-TNF treatment (n=92)

From: Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study

 

Univariable analysis

Multivariable analysis

OR

p-value

OR

p-value

Agea

1.26 (0.82–1.96)

0.296

1.18 (0.73–1.90)

0.509

Female sex

4.31 (0.80–23.27)

0.089

5.92 (1.05–33.46)

0.044

Disease durationb

1.18 (0.75–1.85)

0.469

  

Initial BASDAI (0 month)

0.96 (0.73–1.26)

0.772

  

Initial ASDAS-CRP (0 month)

0.85 (0.54–1.35)

0.493

  

High mSASSS (> median)

1.81 (0.85–3.85)

0.123

1.95 (0.85–4.45)

0.113

Peripheral arthritis

1.31 (0.62–2.77)

0.484

  

Uveitis

0.91 (0.40–2.05)

0.811

  

Psoriasis

1.57 (0.10–25.72)

0.753

  
  1. aRoot-transformed value was used
  2. bLog-transformed value was used
  3. ASDAS Ankylosing Spondylitis Disease Activity Score, CRP C-reactive protein, TNF tumor necrosis factor, OR odds ratio, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, mSASSS modified Stoke Ankylosing Spondylitis Spine Score